Prelude’s CEO, Kris Vaddi, Ph.D., emphasized the significance of PRT2527’s results while outlining future priorities. “These findings confirm our hypothesis that a selective and potent CDK9 ...

I believe Cyclin-Dependent Kinase 9 (CDK9) inhibitors are one modality that will bring us a step closer to that future. By targeting the fundamental processes that enable cancer cell survival ...

Hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide, remains one of the most aggressive malignancies. In a recent study published in Nature Communications, ...

The major focus of our research is on the HIV Tat protein, which is essential for HIV transcription, and on two cellular factors, cyclin T1 and Cdk9, which are necessary for Tat function. We are ...

The company’s focus on SMARCA2 degraders and CDK9 inhibitors has garnered attention from investors and analysts alike, with recent data presentations sparking both optimism and caution.